Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 7/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436222 | 0.89 | ESR2 (0.65) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL490066 | 0.89 | ESR1 (0.65) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL30471045 | 0.89 | ESR2 (0.65) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL30408119 | 0.89 | ESR1 (0.65) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL7838175 | 0.87 | ESR1 (0.55) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL2076811 | 0.87 | ESR1 (0.50) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL3899192 | 0.83 | ESR1 (0.53) | ESR1ESR2PKMCA12CA1 | |
| SCHEMBL6923184 | 0.80 | NOTUM (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25199618 | 0.78 | ESR1 (0.57) | ESR1ESR2ABHD6HDAC8HDAC6 | |
| SCHEMBL30412058 | 0.78 | ESR1 (0.57) | ESR1ESR2ABHD6HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687507-B1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-9035059-B2 | Nitrogen-containing condensed heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-05-19 | — | — | US | disclosed |
| EP-2687507-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005382-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND | LCAT, ACAT2, SOAT2 | ESR1 3324/4885ESR2 1745/4885PKM 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.